To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV

PHASE4CompletedINTERVENTIONAL
Enrollment

604

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

January 25, 2019

Study Completion Date

June 12, 2019

Conditions
VaccinationReaction - Vaccine
Interventions
BIOLOGICAL

Sabin-IPV+bOPV+bOPV

202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively

BIOLOGICAL

Sabin-IPV+Sabin-IPV+bOPV

197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively

BIOLOGICAL

Sabin-IPV+Sabin-IPV+Sabin-IPV

205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively

Trial Locations (1)

010031

Inner Mongolia Autonomous Region Center for Diseases Prevention and Control, Hohhot

All Listed Sponsors
collaborator

Inner Mongolia Autonomous Region Center for Diseases Prevention and Control

UNKNOWN

collaborator

Shaanxi Provincial Center for Disease Control and Prevention

OTHER

collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

collaborator

Peking University

OTHER

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04054492 - To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV | Biotech Hunter | Biotech Hunter